LISTEN LIVE: All Things Considered

Advertisement

 

FDA's plan to diversify clinical trials falls flat, study finds05:37
Download

Play

Five years ago, the Food and Drug Administration began implementing a plan to increase diversity and transparency in its clinical trials of medicines.

So what progress has been made? Well, not nearly enough, according to the reporting of Ed Silverman, a senior writer for STAT.

This segment aired on March 9, 2022.

Advertisement

 

Advertisement

 
/00:00
Close